Drug
MC-1101
MC-1101 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Completed1
Terminated1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
completed133%
terminated133%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_2
Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
NCT02127463
terminatedphase_2
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
NCT01601483
completedphase_1
A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
NCT01013376
Clinical Trials (3)
Showing 3 of 3 trials
NCT02127463Phase 2
Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
NCT01601483Phase 2
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
NCT01013376Phase 1
A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3